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Introduction: Sodium-glucose linked transporter (SGLT) inhibitors could improve glycaemia and simplify
insulin regimens in recent-onset type 1 diabetes (T1D), provided they were well-tolerated and safe. This
study aimed to determine the feasibility and safety of a SGLT inhibitor for the treatment of recent-onset
T1D.
Method: An open label, prospective pilot study in adults with recent-onset T1D was performed.
Empagliflozin, 25 mg orally daily, was given in combination with insulin and multidisciplinary care
during a 24-week treatment phase, followed by wash-out visits at weeks 30 and 36.
Results: Fourteen participants (4 women; median age 26 years) began and 13 completed the study. No
treatment-emergent serious adverse events were observed, with fatigue and genital infection the most
common side-effects. Four participants stopped mealtime insulin for at least one month when taking
empagliflozin. At week 24, median weight, HbA1c and insulin dose decreased by 4.4 kg, 1.5% (17 mmol/
mol) and 0.03 units/kg/day, respectively. Meal-stimulated C-peptide was maintained during the treat-
ment phase and then decreased at 36 weeks.
Conclusions: Treatment of adults with empagliflozin within 100 days of T1D diagnosis appeared safe and
was associated with improved clinical outcomes. These findings justify a definitive trial to determine if
SGLT inhibitors simplify treatment regimens and improve clinical outcomes in recent-onset T1D.
Registration: ACTRN12617000016336.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In people with long-standing type 1 diabetes (T1D), sodium-
glucose cotransporter (SGLT) inhibitors improve glucose control,
decrease insulin requirement and promote weight loss [1], but also
predispose to genital infection and ketoacidosis [2]. SGLT inhibitors
have not been widely used in recent-onset T1D, primarily due to
concern about the risk of ketoacidosis [3]. This would be an un-
reasonable burden for patients to manage while they are adjusting
to their diagnosis and learning how to manage their diabetes.
However, the presence of residual beta cell function at diagnosis of
T1D [4] is likely to decrease the risk of ketosis with SGLT inhibitord Endocrinology, Royal Mel-
ntworth).
r Inc. This is an open access articletreatment [3]. Furthermore, improved postprandial glucose control,
observed in people with long-standing T1D who received sotagli-
flozin [5], may be particularly helpful in recent-onset T1D by
decreasing bolus insulin requirements and simplifying insulin
regimens. An argument can be made to evaluate SGLT inhibition as
a treatment adjunct in recent-onset T1D provided side-effects are
tolerable. Therefore, as a prelude to a randomised control trial, we
first sought to determine the feasibility and safety of the SGLT2
inhibitor, empagliflozin, in patients with recent-onset T1D.
2. Materials and methods
2.1. Patients and setting
The study was conducted at Royal Melbourne Hospital be-
tween January 2017 and May 2019 and registered as
ACTRN12617000016336. Inclusion criteria were age 18-40 years,under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
J.M. Wentworth et al. / Metabolism Open 5 (2020) 1000212T1D diagnosed within 100 days of starting empagliflozin, presence
of at least one islet autoantibody and meal-stimulated plasma C-
peptide >0.07 nmol/L. Exclusion criteria were a co-morbidity
deemed to pose unacceptable risk, pregnancy or planned preg-
nancy, breast feeding or, if female, refusal to use effective
contraception.
2.2. Interventions and data collection
At weeks 0, 12, 24 and 36, participants undertook routine
biochemistry, completed a diabetes distress survey [6] and wore a
Minimed™ iPro™2 continuous glucose monitor (CGM; Medtronic
Minimed™, Northridge, CA) for one week. Mixed meal tolerance
tests were performed at the same intervals to determine beta-cell
function, calculated by dividing the trapezoidal area under the C-
peptide curve by 120 min [7]. Empagliflozin was withheld three
days prior to meal tests at weeks 12 and 24 to avoid potential ef-
fects on C-peptide release.
At weeks 4, 8, 18 and 30, additional visits were scheduled to
review glucose control. Participants accessed dietician and diabetes
educator support at all study visits to target fasting and post-
prandial glucose to 5 mmol/L and 10 mmol/L respectively. They
monitored capillary ketone concentrations weekly using an Optium
Neo device (Abbott, Doncaster, Australia).
Adherence with empagliflozin (25 mg daily from weeks 0e24)
was assessed by urine dipstick testing for glucose and by counting
tablets.
2.3. Outcomes
The primary outcome of feasibility was assessed as adherence
with the study protocol and safety. Secondary outcomes were
numbers and severity of adverse events, bodyweight, stimulated C-
peptide, HbA1c, insulin dose, CGM measures and diabetes distress
score [6].
2.4. Statistical analyses
Data were complete with the exception of CGM results at week
12 for one participant, which were imputed by averaging the
measures at 0 and 24 weeks. Statistical analyses were performed
with Prism software (V8, GraphPad, San Diego, CA). The Friedman
test was used to assess differences across time, with correction for
multiple comparisons by the two-stage linear step-up procedure of
Benjamini, Krieger and Yekutieli [8].
3. Results
3.1. Participant recruitment and baseline characteristics
Sixty-one individuals were referred to the study. Fifteen did not
meet eligibility and 32 declined to participate due to perceived
treatment risks and the study demands. All 14 participants who
enrolled were on multiple daily insulin injections. Their baseline
characteristics are presented in Table 1. Median [Q1, Q3] age was 26
[22, 32] years, body mass index 24 [23, 26] kg/m2, disease duration
72 [54, 92] days and HbA1c 7.1 [6.1, 8.5] percentage units (54 [42,
69] mmol/mol).
3.2. Medication adherence and safety
The median rate of empagliflozin adherence was 0.89 [0.74, 1.0].
Four serious adverse events (SAEs) affecting four participants were
observed. One (alcohol intoxication without ketosis) occurred
during week 24 and the other three (concussion, finger dislocationand supraventricular tachycardia) occurred during weeks 24e36,
after empagliflozin was ceased.
3.3. Other adverse events
During weeks 0e24, 14 episodes of generalised fatigue affected
9 participants. These episodes were associated with capillary blood
glucose readings in the lower range (between 3.5 and 6 mmol/l)
and resolved after 1-5 days in 7 of the affected participants. How-
ever, fatiguewas sufficiently severe to prompt 2 participants to stop
taking empagliflozin: one noted fatigue in week 1 and withdrew
from the trial; the other took the tablet intermittently over the first
10 weeks due to fatigue before stopping it. On re-exposure during
week 16, fatigue recurred and no further doses were taken. In
addition, 5 episodes of mild to moderate genital infection affected
four participants, all of whom received topical or oral anti-fungal
treatment for up to a week and continued taking empagliflozin.
3.4. Capillary ketone measures
During the 24-week empagliflozin treatment phase, the 13
participants who completed the study performed amedian [Q1, Q3]
of 35 [20, 66] home capillary ketone measurements, only one of
which exceeded 1mmol/l. This occurred inweek 15 associatedwith
headache, that resolved after 4 h, when ketones were 0.6 mmol/l.
3.5. Diabetes outcomes
After 24 weeks, median body weight decreased by 4.4 kg and
median HbA1c by 1.5% units (17 mmol/mol; Fig. 1a and b). Insulin
doses decreased to week 24 and then increased (Fig. 1c), with 4
participants stopping bolus insulin for at least a month. Meal-
stimulated C-peptide did not change significantly during the first
24 weeks and then decreased (Fig. 1d and e). CGM mean glucose
decreased initially and then increased between weeks 12 and 36
(Fig. 1f), while glucose time within and below range, and %CV did
not change significantly (Fig. 1g, h, i). Diabetes distress did not
change significantly (Fig. 1j).
4. Discussion
We demonstrate a high level of treatment adherence and no
concerning ketosis or other adverse events when empagliflozin
25 mg daily was combined with basal/bolus insulin therapy within
100 days of T1D diagnosis. Empagliflozin treatment was associated
with decreased body weight and improved glucose control despite
decreased frequency and doses of insulin injections. Together, these
findings demonstrate the feasibility of this approach to T1D ther-
apy, and suggest it may deliver clinical benefit.
Strengths of this study include the prospective collection of
measures of capillary ketones, CGM data and beta-cell function
(meal-stimulated C-peptide). Ketoacidosis is reported to occur at a
rate of 5 events per 100 patient years in established T1D [3]. Our
sample size was too small to determine the risk of ketoacidosis but
the finding of only one home ketone measurement over 1 mmol/l
suggests it was not increased by treatment with empagliflozin.
Glucose time in the 3.9e10 mmol/l range did not improve during
empagliflozin treatment, in contrast to prior studies of SGLT in-
hibitors in long-standing T1D [5,9,10]. However, at baseline, the
percentage of time in range was much lower in these studies (40-
52% compared to 83% in this study), so any change with SGLT in-
hibitor treatment would have been smaller in magnitude and
therefore more difficult to detect. Meal-stimulated C-peptide did
not change significantly during the 24-week treatment phase,
indicating no substantial effect of empagliflozin on beta-cell
Table 1
Baseline characteristics.
ID Sex Age
(years)
Diabetes
durationa (days)
Weight
(kg)
BMI
(kg/m2)
DKA at
diagnosis
Polyuria/polydipsia
at diagnosis
Antibody
specificity
HLA-DR
genotype
HbA1c
(%)
HbA1c
(mmol/mol)
Insulin dose
(U/kg/day)
Stimulated C-
peptide (nmol/l)
1 M 31 58 95.3 26.4 Yes Yes GAD, ZnT8 4/X 8.3 67 0.24 0.524
2 F 18 92 84.1 33.7 No No GAD, ZnT8 4/X 6.0 42 0.27 1.169
3 M 22 92 63.7 21.5 Yes Yes GAD 3/3 6.0 42 0.36 0.489
4 F 34 94 77.7 25.1 Yes Yes GAD NP 6.5 47 0.12 0.640
5 M 22 72 81.2 25.9 No Yes GAD, IA2 4/X 5.9 41 0.15 0.920
6 M 27 80 84.0 24.0 No Yes GAD, IA2 4/4 8.1 65 0.18 0.399
7 M 18 96 82.9 26.2 No Yes GAD, IA2,
ZnT8
3/3 5.9 41 0.44 0.493
8 M 22 55 82.9 24.2 No Yes GAD, IA2,
ZnT8
3/4 7.6 60 0.11 1.042
9 M 27 72 80.0 25.0 No Yes GAD 3/4 6.5 48 0.40 1.084
10 F 37 28 64.5 22.5 No Yes ZnT8 4/X 10.4 90 0.22 0.392
11 M 31 72 76.1 24.0 No Yes GAD, IA2,
ZnT8
3/4 6.5 48 0.12 0.435
12 M 22 68 65.8 22.8 No Yes GAD 3/X 9.5 80 1.52 0.283
13 F 25 50 56.3 19.7 No Yes GAD, ZnT8 3/3 8.9 74 0.52 0.865
14 M 36 28 71.8 23.3 No Yes GAD, ZnT8 4/X 7.9 63 0.35 0.552
NP: not performed.
a at time of taking first dose of empagliflozin.
Fig. 1. Clinical outcomes for the 13 participants who completed the study. Weight (a), HbA1c (b), insulin dose (c), meal-stimulated C-peptide (d, e), CGM measures of mean daily
glucose (f), time between 3.9 and 10 mmol/L (g), time <3.9 mmol/L (h) and glucose variability %CV (i), and diabetes distress score (j) are shown as median with interquartile range.
The grey shaded area corresponds to the empagliflozin treatment phase from weeks 0e24. *, ** and *** depict p < 0.05, <0.01 and < 0.001 respectively.
J.M. Wentworth et al. / Metabolism Open 5 (2020) 100021 3function. The significant decrease in C-peptide between weeks 24
and 36 during the washout phase does however raise the possi-
bility that empagliflozin might preserve beta-cell function in
recent-onset T1D. Because the visit schedule of this study mirrored
that used by trials of disease-modifying therapy in T1D (e.g.
Ref. [11]), our outcome data should aid the design of a placebo-
controlled trial involving a similar population to determine the
effects of SGLT inhibition on beta-cell function.
This study identified two common adverse events that may limit
tolerability of SGLT inhibitors in recent-onset T1D. Genital infectionwas not unexpected [9,10,12] and was mild to moderate in severity.
However, the observation of generalised fatigue affecting 9 par-
ticipants and causing 2 to stop empagliflozin treatment early was
unexpected. Its association with low-normal capillary glucose
measures suggests this side-effect might be alleviated by gradual
dose escalation of empagliflozin.5. Conclusion
Our findings provide support for a definitive trial to determine
J.M. Wentworth et al. / Metabolism Open 5 (2020) 1000214the effects of SGLT inhibitors on clinical outcomes and on beta-cell
function, either alone or in combination with newer non-insulin
therapies [11,13].
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